PRATOSARTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H26N6O
Molecular Weight	426.5135
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5)C(=O)CCCC2

InChI

InChIKey=KCTFTBCZZUBAKN-UHFFFAOYSA-N

InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)

HIDE SMILES / InChI

Molecular Formula	C25H26N6O
Molecular Weight	426.5135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18360048 | https://adisinsight.springer.com/drugs/800002623 | https://www.medchemexpress.com/Pratosartan.html

Pratosartan is an orally active angiotensin II type 1 receptor blocker. It is being developed for the treatment of hypertension. Pratosartan was efficacious throughout the long-term study, without serious adverse effects. Pratosartan significantly decreased serum total cholesterol in patients with hypercholesterolemia and uric acid in patients with hyperuricemia. It may have beneficial effects on hypertensive patients with some metabolic disorders. Pratosartan is still in phase III development in South Korea and phase II in Japan for hypertension.

Approval Year

PubMed

Title	Date	PubMed
Antihypertensive effect of chronic KT3-671, a structurally new nonpeptide angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats.	1995 Nov	8699629
Synthesis and pharmacological activity of the metabolites of Pratosartan.	2006 Jun	16755044
Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3h-cycloheptimidazol-4-ones and 2-alkyl-3h-cycloheptimidazol-4-ones.	2006 May	16651773
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.	2007 Jan	17043154
Effects of angiotensin II receptor blockers on renal handling of uric acid in rats.	2008	18762713
Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients.	2008 Feb	18360048
Gateways to clinical trials. July-August 2008.	2008 Jul-Aug	18850047
Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.	2008 Mar	17674156

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 16 18:15:51 UTC 2022` Edited by `admin` on `Fri Dec 16 18:15:51 UTC 2022`
Record UNII	66VLQ6E6DL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRATOSARTAN

Official Name

English

KT3-671

Code

English

Pratosartan [WHO-DD]

Common Name

English

pratosartan [INN]

Common Name

English

PRATOSARTAN [JAN]

Common Name

English

DA-727

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C66930